TABLE 3.

Group comparisons of measured parameters^a

Parameter	Analysis	Unit of analysis	Subgroup 1				Subgroup 2				Test	P
			Subgroup name	n	Median	IQR	Subgroup name	n	Median	IQR
Total plasma NT70 ()	I	Heterologous virus NT70	Pretreatment	14	40	40-84	Wk 12	14	482	342-578	W	0.0001
	II	Heterologous virus NT70	Wk 12	13b	436	342-551	Wk 24	13	113	55-154	W	0.0046
	III	Heterologous virus NT70	Responders	6	501	373-553	Nonresponders	8	361	327-667	M	0.491
	IV	Autologous virus NT70	Responders	6	732	175-1,808	Nonresponders	8	234	147-703	M	0.414
MAb NT70 ()	V	Heterologous virus NT70		14	350	205-455		14	78	40-122	M	<0.0001
	VI	Heterologous virus NT70		14	350	205-455		14	30	18-44	M	<0.0001
	VII	Heterologous virus NT70	Responders	6	514	468-618	Nonresponders	8	317	260-552	M	0.181
	VIII	Autologous virus NT70	Responders	6	614	192-1,520	Nonresponders	8	95	35-149	M	0.0127
	IX	Autologous virus NT70; pretreatment	Acute	6	40	40-40	Chronic	8	110	93-243	NAc
	X	Autologous virus NT70; wk 24	Acute	6	168	51-455	Chronic	7	178	160-2,062	M	0.366
Autologous-Ab NT70 ()	XI	Autologous virus NT70	Responders	6	10	10-1,036	Nonresponders	8	165	85-399	M	0.0813
Fold difference	XII		Responders	6	43.3	2.74-152	Nonresponders	8	0.63	0.07-16.2	M	0.0293
	XIII		Responders without NAB14d	5	74.2	8.9-152	Nonresponders	8	0.63	0.07-16.2	M	0.0062

^aIQR, interquartile range; W, Wilcoxon signed rank test; M, Mann-Whitney U test; NA, not applicable; Ab, antibody.

^bPatient NAB06 reinititated antiretroviral therapy after week 12; thus, data from only 13 patients are available for group comparison of weeks 12 and 24.

^cGroup comparison not applicable, because at the pretreatment time point, no neutralization activity was detectable in acute infection; the NT range for chronic infection was 71 to 965.

^dPatient NAB14 was excluded from the analysis.